This was a retrospective subgroup analysis of data from a multicenter , randomized , phase III clinical trial evaluating pemetrexed + carboplatin versus docetaxel + carboplatin in elderly chemo-naive patients with advanced , nonsquamous non-small cell lung cancer ( NSCLC ) .